Half Year 2025 Smith & Nephew PLC Earnings Call Transcript
Key Points
- Smith & Nephew PLC (SNN) reported a 6.7% underlying revenue growth in the second quarter, reflecting acceleration across all regions and business units.
- The company achieved a 100 basis points expansion in trading margin in the first half, slightly ahead of expectations due to efficiency savings.
- Smith & Nephew PLC (SNN) announced a $500 million share buyback in the second half of 2025, funded by operational efficiencies and cash flow.
- The company reported a 70% increase in trading cash flow and nearly $250 million in free cash flow for the first half of 2025.
- Advanced Wound Devices revenue grew by 12.7%, driven by the single-use negative pressure platform, PICO, and strong growth from the Leaf patient monitoring system.
- Emerging markets declined by 0.2%, with China being a significant headwind due to volume-based procurement impacts.
- The company faces a net headwind of $15 million to $20 million in 2025 due to tariffs, with uncertainty about where tariffs will settle.
- US Knee growth was softer due to a slowdown in procedures and portfolio rationalization efforts, impacting top-line growth.
- The proposed updates to Medicare reimbursement for skin substitutes could be a headwind to Advanced Wound Management sales and profitability in 2026.
- Smith & Nephew PLC (SNN) experienced a decline in infection management within Advanced Wound Care, offsetting growth in other areas.
Welcome to the Smith & Nephew second quarter and first half results meeting. I'm Deepak Nath, I'm the Chief Executive Officer, and joining me is Chief Financial Officer,
So 2025 is a key year of delivery for Smith & Nephew. I'm pleased to announce the results that put us firmly on track for both our full year growth target and the guided step-up in profitability. On revenue, 6.7% underlying growth in the quarter reflects sequential acceleration across all regions and business units.
In Sports Medicine, we've maintained the strong momentum across Joint Repair and AET outside of China. In Wound, the continued performance of AWD and the rebound in bioactives produced double-digit growth for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
